#191 Hepatorenal Syndrome Part 2 on Management: 5 Pearls Segment

This episode addresses the treatment of hepatorenal syndrome (HRS), emphasizing the importance of raising mean arterial pressure (MAP) using vasoconstrictors. It explores three vasoconstrictor options: terlipressin, norepinephrine, and midodrine-octreotide, weighing their effectiveness and side effects. The discussion highlights a study suggesting a MAP increase of greater than 15 mmHg yields the best outcomes. The role of albumin is also examined, cautioning against overuse due to potential respiratory complications, and advocating for its use only to achieve euvolemia. Additionally, the podcast tackles the complexities of volume management, including when diuretics are appropriate, even accepting some hypercreatininemia for clinical improvement. Finally, it confronts the difficult realities of end-stage HRS, discussing liver transplant candidacy, dialysis as a bridge, and palliative care options when transplant isn't feasible.